Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views

References

• Clark RE. Tyrosine kinase inhibitor therapy discontinuation for patients with chronic myeloid leukaemia in clinical practice. Curr Hematol Malig Rep. 2019;14(6):507–514.
   PubMed Web of Science ®Google Scholar
• Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346–357.
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336–1343.
   PubMed Web of Science ®Google Scholar
• Thielen N, Visser O, Ossenkoppele G, et al. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol. 2016;97(2):145–154.
   PubMed Web of Science ®Google Scholar
• Janssen JJWM, Boekhorst PAW, Posthuma EFM, et al. Richtlijn chronisch myeloide leukemie [Guidelines for chronic myeloid leukemia] [Internet]. The Netherlands: 2018. [cited 2020 Jun 29]. Available from: https://hematologienederland.nl/wp-content/uploads/2019/07/hovon-cml-richtlijn-14-04-2018_geautoriseerd.pdf.
   Google Scholar
• Integraal Kankercentrum Nederland. Dataselectie [data selection] [Internet]. The Netherlands: 2020. [cited 2020 Jun 23]. Available from: https://www.iknl.nl/.Dutch.
   Google Scholar
• Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Hewison A, Atkin K, McCaughan D, et al. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: a thematic synthesis of qualitative studies. Eur J Oncol Nurs. 2020;45:101730.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186–e193.
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757.
   PubMed Web of Science ®Google Scholar
• Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650–659.
   PubMed Web of Science ®Google Scholar
• Legros L, Nicolini FE, Etienne G, French Intergroup for Chronic Myeloid Leukemias, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123(22):4403–4410.
   PubMed Web of Science ®Google Scholar
• Fava C, Rege-Cambrin G, Dogliotti I, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104(8):1589–1596.
   PubMed Web of Science ®Google Scholar
• Legros L, Nicolini FE, Etienne G, et al. The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt [abstract]. Blood. 2019;134(Supplement_1):28–28.
   Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv41–iv51.
   PubMed Web of Science ®Google Scholar
• Radich JP, Deininger M, Abboud CN, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(9):1108–1135.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Saglio G, Sharf G, Almeida A, et al. Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective. Clin Lymphoma Myeloma Leuk. 2018;18(6):375–379.
   PubMed Web of Science ®Google Scholar
• Sanford D, Kyle R, Lazo–Langner A, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol. 2014;21(2):e241–e249.
   PubMed Web of Science ®Google Scholar
• Flynn KE, Myers JM, D'Souza A, et al. Exploring patient decision making regarding discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia. Oncologist. 2019;24(9):1253–1258.
   PubMed Web of Science ®Google Scholar
• Lou J, Huang J, Wang Z, et al. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey. Patient Prefer Adherence. 2018;12:1025–1032.
   PubMed Web of Science ®Google Scholar
• Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy [abstract. Blood. 2015;126(23):1584–1584.
   Web of Science ®Google Scholar
• Jiang Q, Liu Z-C, Zhang S-X, et al. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142(7):1539–1547.
   PubMed Web of Science ®Google Scholar
• Boquimpani CM, Szczudlo T, Mendelson E, et al. Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR) [abstract]. Blood. 2014;124(21):4547–4547.
   Web of Science ®Google Scholar
• Villemagne Sanchez LA, O'Callaghan C, Gough K, et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma. 2018;59(2):406–415.
   PubMed Web of Science ®Google Scholar
• Sharf G, Marin C, Bradley JA, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34(8):2102–2112.
   PubMed Web of Science ®Google Scholar
• Chan AHY, Horne R, Hankins M, et al. The medication adherence report scale (MARS‐5): a measurement tool for eliciting patients' reports of non‐adherence. Br J Clin Pharmacol. 2020;86(7):1281–1288.
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CCLM, Kropff F, et al. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol. 2014;53(2):259–267.
   PubMed Web of Science ®Google Scholar
• Royston P, Moons KGM, Altman DG, et al. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009;338:b604.
   PubMed Web of Science ®Google Scholar
• Sogawa R, Kimura S, Yakabe R, et al. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Int J Clin Oncol. 2018;23(5):974–979.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
   PubMed Web of Science ®Google Scholar
• Boons CC, Harbers L, Timmers L, et al. Needs for information and reasons for (non) adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines. Eur J Haematol. 2018;101(5):643–653.
   Web of Science ®Google Scholar
• Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626–630.
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Faryal R, O'Dwyer M, et al. Patient-initiated discontinuation of tyrosine kinase inhibitor for chronic myeloid leukemia. Case Rep Hematol. 2020;2020:9571691. doi: 10.1155/2020/9571691.
   PubMed Web of Science ®Google Scholar
• Wu S, Chee D, Ugalde A, et al. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: a qualitative study. Palliat Support Care. 2015;13(2):255–263.
   PubMed Web of Science ®Google Scholar
• Devos T, Verhoef G, Steel E, et al. Interruption or discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia: a retrospective cohort study (SPARKLE) in Belgium. Acta Haematol. 2019;142(4):197–207.
   PubMed Web of Science ®Google Scholar
• Mortensen GL, Mourek J. Drivers and barriers to medication adherence in patients with chronic myeloid leukaemia: a qualitative study. J Hematol Oncol. 2017;3(1):1–15.
   Google Scholar